Table 3

 Health status at baseline and 52 weeks of patients with RA receiving MTX, etanercept or combination therapy with MTX and etanercept, as measured by least squares mean (95% CI) for EuroQol health status visual analogue scale, patient global assessment, and patient general health visual analogue scale (LOCF analyses)

Methotrexate (n = 228)Etanercept (n = 223)Combination (n = 231)
BaselineWeek 52BaselineWeek 52BaselineWeek 52
EQ-5D VAS, EuroQoL health status visual analogue scale; PGAD, patient global assessment; GHVAS, patient general health visual analogue scale.
†p<0.01 for combination versus MTX; ‡,‡p<0.01 and p<0.05, respectively, for combination versus etanercept.
EQ-5D VAS38.74 (35.74 to 41.73)63.66 (60.48 to 66.84)43.12 (40.07 to 46.17)66.75 (63.51 to 70.00)40.74 (37.77 to 43.71)72.71 (69.57 to 75.85)†‡
PGAD6.85 (6.61 to 7.09)3.95 (3.63 to 4.27)6.86 (6.61 to 7.10)3.83 (3.50 to 4.15)7.16 (6.92 to 7.40)2.88 (2.56 to 3.20)†‡
GHVAS68.88 (66.15 to 71.61)36.28 (33.09 to 39.46)68.96 (66.19 to 71.74)35.32 (32.08 to 38.56)70.02 (67.31 to 72.72)24.80 (21.65 to 27.94)†‡